Filing Details
ImmunityBio, Inc. (NASDAQ:IBRX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 04, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:IBRX
ImmunityBio, Inc. (IBRX) Files Quarterly Report for Q0
Filing Details ImmunityBio, Inc. (NASDAQ:IBRX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 04, 2026. The Healthcare company…
Market Context
ImmunityBio, Inc.'s stock currently trades at $6.95 with a market capitalization of $2.2B.
The 10-Q provides ImmunityBio, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for ImmunityBio, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View IBRX Stock Page
Frequently Asked Questions
Where can I read IBRX's SEC filings?
Browse all filings on our IBRX SEC filings page.
What types of SEC filings does ImmunityBio, Inc. file?
Public companies like ImmunityBio, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.